Strong Performance Leads to Generous Compensation for New CFO: A Strategic Move by Heart Device Company

Edwards Lifesciences Corp (EW) offered its incoming Chief Financial Officer, Doretta Mistras, a substantial compensation package that includes a $925,000 annual base salary, a cash signing bonus of approximately $2 million, and $8 million in restricted stock units—amounts that translate into several billion Korean won. Mistras accepted the offer on May 2.

The company’s long-term, performance-linked employment terms also include annual stock awards, performance bonuses, cash severance and change-in-control compensation with accelerated equity vesting, relocation assistance from New York to Orange County, and reimbursement of legal fees.

In its first-quarter results, Edwards Lifesciences reported net sales of $1.65 billion—up 16.7% year-over-year—and, driven by double-digit growth in transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT), raised its full-year revenue growth and adjusted EPS guidance.

At the end of April, the company announced that it will present at the Bank of America Securities 2026 Healthcare Conference and Citi’s 2026 Unplugged MedTech & Life Sciences Access Day, where management will provide updates on recent performance and its structural heart therapy portfolio.

Headquartered in Irvine, California, Edwards Lifesciences is a global medical device company specializing in catheter-delivered heart valves for structural heart disease, as well as related surgical and critical-care monitoring equipment.

With an aging population and the expansion of minimally invasive cardiac procedures fueling growth in the structural heart device market—including TAVR and TMTT—Edwards Lifesciences is recognized as one of the leading global players in this field.